CONECTA® Platform
Superior starting points
Predictable discovery of highly effective oral medicines that do the job of biologics
CONECTA® is an AI-powered drug discovery platform opening access to the vast diversity of nature-encoded chemistry, turning unexplored molecules into the predictable discovery of oral therapies.
CONECTA Platform
Predictable path to multiple leads and DCs with diverse chemotypes and mechanisms
Untapped chemistry
We unlock access to a massive, untapped chemical space of over 3 billion novel compounds, opening entirely new opportunities for drug discovery
Biology-first approach
Our mechanism-agnostic approach precisely matches this diverse chemistry to disease biology, engaging conventionally hard-to-drug targets
Unlock complex targets
With our privileged chemistry and platform, complex protein targets are now within reach, including those with no known binding pockets
Untapped bioactive chemical space, unprecedented scale
We are building the world’s largest curated collection of Anthromolecules® – bioactive compounds evolved by nature to have biological activity that humans have safely consumed for centuries. Inspired by their richly diverse structures, our proprietary drug discovery platform retains the unique three-dimensional structures of this chemistry and engineers them to improve their drug-like properties.
Discovering chemistry outside the realm of most traditional libraries
3B+ novel compounds
We unlock access to a massive, untapped chemical space of over 3 billion novel compounds, opening entirely new opportunities for drug discovery
99% unique scaffolds
Our Anthromolecule library features molecular scaffolds with rich three-dimensional structures with bioactivity history, compelling drug-like properties and accessibility to engage complex biology with precision and selectivity
Multiple mechanisms
Covalent binders, allosteric modulators, molecular glues, macrocycles, protein-protein interaction inhibitors, all written by nature, allowing a universal search for connections to biological targets
Precision pathway connections to target biology
CONECTA® is powered by advanced multimodal foundation models trained on over 3 billion curated and proprietary data points and 100 biological pathways across five therapeutic areas. By systematically mapping our massive chemical space to the complex biological drivers of disease, CONECTA® enables predictable, repeatable discovery of breakthrough oral medicines.
CONECTA precision-matches diverse chemistry to precisely deliver target biological outcomes with high efficiency
Superior hit rates
Our platform demonstrates an 80X higher hit rate vs. traditional drug screening, and 9X higher even than industry-leading public machine learning models
60+ predictive models
We utilize a suite of more than 60 state-of-the-art predictive models to precisely filter and optimize for drug-like properties; integrated AI models rapidly accelerate insight generation, equal to running 1,000 years of experiments in less than 2 days
Hit to candidate in 24 months
Our platform dramatically accelerates programs with focused medchem, turning hits into potent, selective and safer oral candidates in ~24 months
Integrating human and machine expertise to transform possibilities
Conventional drug discovery happens in silos. The CONECTA® platform unites our entire team of experts across disciplines – biologists, chemists, toxicologists, CMC, and drug developers – to evaluate, optimize and advance programs more efficiently and effectively.
Together with our machine learning experts, this integrated team defines a precise target candidate profile from day one, using AI to rapidly uncover and advance multiple distinct, high-potential drug candidates.
AI-powered integrated decisioning weighs risks, trade-offs, and benefits at once—breaking silos for better options
Supercharged drug developers
AI systems help our scientists define and deliver precision drug profiles with efficiency and speed, reducing operational overhead by 80%
Smarter candidates
Combining multidisciplinary expertise with AI ensures a focus on viable candidate selection, clarifying risks and opportunities to save time and effort
Higher probability of success
By delivering multiple independent candidates across a range of disease targets, we aim to maximize our clinical optionality and significantly de-risk our pipeline
Raising the odds of success
Through a highly integrated, AI-driven approach, the CONECTA platform empowers our drug developers to unearth effective, safe and accessible oral solutions that can solve the hardest biological challenges in chronic inflammatory disease.
See the productivity of the CONECTA platform in our pipeline.